Systemic sclerosis: Epidemiology and environmental factors;Sclérodermie systémique: Épidémiologie et facteurs environnementaux

Presse Medicale

Volumn 35, Issue 12 C2, 2006, Pages 1894-1901

  Magnant, Julie ^a   Diot, Elisabeth ^a  

^a CHU BRETONNEAU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPOXY RESIN; SILICON;

CASE CONTROL STUDY; ENVIRONMENTAL FACTOR; FUME; HUMAN; OCCUPATIONAL EXPOSURE; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; SYSTEMIC SCLEROSIS; VIBRATION; WORKMAN COMPENSATION;

EID: 33845488345     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(06)74923-5     Document Type: Review

References (51)

1. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980; 23: 581-90.
2. De Juan MD, Belzunegui J, Belmonte I. An immunogenetic study of familial scleroderma. Ann Rheum Dis. 1994; 53: 614-7.
3. Bramwell B. Diffuse scleroderma its frequency, the occurrence in stone-masons: its treatment by fibrolysin-elevations of temperature due to fibrolysin injections. Edinburgh Med J. 1914; 12: 387-401.
4. Aryal BK, Khuder SA, Schaub EA. Meta-analysis of systemic sclerosis and exposure to solvents. Am J Ind Med. 2001; 40: 271-4.
5. Diot E, Lesire V, Guilmot JL, Metzger MD, Rogier S, Stadler M et al. Systemic sclerosis and occupational risk-factors: a case-control study. Occup Environ Med. 2002; 59: 545-9.
6. Czirjak L, Kumanivics G. Exposure to solvents in female patients with scleroderma. Clin Rheumatol. 2002; 21: 114-8.
7. Garabrant DH, Lacey JV, Laing TJ, Gillespie BW, Mayes MD, Cooper BC. Scleroderma and solvents exposure among Women. Am J Epidemiol. 2003; 157: 493-500.
8. Bovenzi M, Barbone F, Pisa FE, Betta A, Romeo L, Tonello A et al. A case-control study of occupational exposures and systemic sclerosis. Int Arch Occup Environ Health. 2004; 77: 10-6.
9. Maître A, Hours M, Bonneterre V, Arnaud J, Tülin Arslan M, Carpentier P et al. Systemic sclerosis and occupational Risk factors: role of solvents and cleaning products. J Rheumatol. 2004; 31: 2395-401.
10. Silman AJ, Howard Y, Hicklin AJ, Black C. Geographical clustering of scleroderma in south and west London. Br J Rheumatol. 1990; 29: 93-6.
11. Valesini G, Litta A, Bonavita MS, Luan FL, Purpura M, Mariani M et al. Geographical clustering of scleroderma in a rural area in the province of Rome. Clin Exp Rheumatol. 1993; 11: 41-7.
12. Englert H, Joyner J, Bade R, Thompson M, Morris D, Chambers P et al. Systemic sclerosis: a spatiotemporal clustering. Intern Med J. 2005; 35: 228-33.
13. Tamaki T, Mori S, Takehara K. Epidemiological study of patients with systemic sclerosis in Tokyo. Arch Dermatol Res. 1991; 283: 366-71.
14. Alamanos Y, Tsifetaki N, Voulgari PV, Siozos C, Tsamandouraki K, Alexiou GA et al. Epidemiology of systemic sclerosis in northwest Greece 1981 to 2002. Semin Arthritis Rheum. 2005; 34: 714-20.
15. Le Guern V, Marh A, Mouthon L, Jeanneret D, Carzon M, Guillevin L. Prevalence of systemic sclerosis in a French multi-ethnic county. Rheumatology. 2004; 43: 1129-37.
16. Mayes MD, Lacey Jr JV, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ et al. Prevalence, incidence, survival and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003; 48: 2246-55.
17. Thompson AE, Pope JE. Increased prevalence of scleroderma in south-western Ontario: a cluster analysis. J Rheumatol. 2002; 29: 1867-73.
18. Roberts-Thomson PJ, Jones M, Hakendorf P, KencanaDharmapatni AA, Walker JG, MacFarlane JG et al. Scleroderma in South Australia: epidemiological observations of possible pathogenic significance. Intern Med J. 2001; 31: 220-9.
19. Englert H, Small-McMahon J, Davis K, O'Connor H, Chambers P, Brooks P. Systemic sclerosis prevalence and mortality in Sydney 1974-88. Aust N Z J Med. 1999; 29: 42-50.
20. Arnett FC, Howard RF, Tan F, Moulds JM, Bias WB, Durban E et al. Increased prevalence of systemic sclerosis in a native American tribe in Oklahoma. Arthritis Rheum. 1996; 39: 1362-70.
21. Erasmus LD. Scleroderma in gold-miners on the Witwatersrand with particular reference to pulmonary manifestations. S Afr J Labor Clin Med. 1957; 3: 209.
22. Rodnan GP, Benedek TG, Medsger TA Jr, Cammarata RJ. The association of progressive systemic sclerosis (scleroderma) with coal miner's pneumoconiosis and other forms of silicosis. Ann Intern Med. 1967; 66: 323-34.
23. Sluis-Cremer GK, Hessel PA, Nizdo EH, Churchill AR, Zeiss EA. Silica, silicosis and progressive systemic sclerosis. Br J Ind Med. 1985; 42: 838-43.
24. Haustein UF, Anderegg ULF. Silica induced scleroderma - Clinical and experimental aspects. J Rheumatol. 1998; 25: 1917-26.
25. Burns CJ, Laing TJ, Heeringa SC, Alcser KH, Mayes MD, Wasko MC et al. The epidemiology os scleroderma among women: assessment of risk from exposure to silicone and silica. J Rheumatol. 1997; 23: 904-11.
26. Rosenman KD, Moore-Fuller M, Reilly MJ. Connectivite tissue disease and silicosis. Am J Ind Med. 1999; 35: 375-81.
27. Calvert GM, Rice FL, Boiano JM, Sheehy JW, Sanderson WT. Occupational silica exposure and risk of various diseases: an analysis using death certificates from 27 states of United States. Occup Environ Med. 2003; 60: 122-9.
28. Bovenzi M, Barbone F, Bettava A, Tommasini M, Versini W. Scleroderma and occupational exposure. Scand J Work Environ Health. 1995; 21: 289-92.
29. Englert H, Small-McMahon J, David K, O'Connor H, Chambers P, Brooks P. Male systemic sclerosis and occupational silica exposure - a population-based study. Aust N Z J Med. 2000; 30: 215-20.
30. Vigliani EC, Pernis B. Immunological aspects of silicosis. Ad Tuberc Res. 1963; 12: 230-72.
31. Hallé O, Schaeverbeke T, Bannwarth B, Dehais J. Les facteurs d'environnement et les éléments iatrogènes dans la sclérodermie systémique et les syndromes apparentés. Rev Med Interne. 1997; 18: 219-29.
32. Steenland K, Goldsmith DF. Silica exposure and autoimmune diseases. Am J Ind Med. 1995; 28: 603-8.
33. Reinl W. Sklerodermie durch trichloräthylen-einwirkung? Zent f Arbeitsmed u Arbettsschutz. 1957; 7: 58-60.
34. Walder B. Solvents and scleroderma. Lancet. 1965; II: 436.
35. Goldman JA. Connectivite tissue disease in people exposed to organic chemical solvents. Systemic sclerosis (scleroderma) in dry cleaning plant and aircraft industry workers. J Clin Rheumatol. 1996; 2: 185-90.
36. Fessel WJ. Scleroderma and welding. N Engl J Med. 1977; 296: 1537.
37. Kumagaï Y, Abe C, Shiokawa Y. Scleroderma after cosmetic surgery. Arthritis Rheum. 1979; 22: 532.
38. Janowsky EC, Kupper LL, Hulka BS. Meta-analyses of the relation between silicone breast implants and the risk of connectivite-tissue diseases. New Engl J Med. 2000; 342: 781-90.
39. Pelmear PL, Roos JO, Maehle WM. Occupationally-induced scleroderma. J Occup Med. 1992; 34: 20-5.
40. Blair HM, Headington JT, Lynch PJ. Occupational trauma, Raynaud phenomenon, and sclerodactylia. Arch Environ Health. 1974; 28: 80-1.
41. Bovenzi M, Barbone F, Pisa FE, Betta A, Romeo L. Scleroderma and occupational exposure to hand-transmitted vibration. Int Arch Occup Environ Health. 2001; 74: 579-82.
42. Yamakage A, Ishikawa H, Saito Y, Hattori A. Occupational scleroderma-like disorders occurring in men engaged in the polymerisation of époxy resins. Dermatologica. 1980; 161: 33-44.
43. Silman AJ, Jones S. What is the contribution of occupational environmental factors to the occurrence of scleroderma in men? Ann Rheum Dis. 1992; 51: 1322-24.
44. Rustin MH, Bull HA, Ziegler V, Mehlhorn J, Haustein UF, Maddison PJ et al. Silica-associated systemic sclerosis in clinically, serologically and immunologically indistinguishable from idiopathic systemic sclerosis. Br J Dermatol. 1990; 123: 725-34.
45. Nietert PJ, Sutherland SE, Silver RM, Pandey JP, Dosemeci M. Solvent oriented hobbies and the risk of systemic sclerosis. J Rheumatol. 1999; 26: 2369-72.
46. Mac Hugh NJ, Whyte J, Harvey G, Haustein UF. Anti-topoisomerase I antibodies in silica-associated systemic sclerosis. Arthritis Rheum. 1994; 37: 1198-205.
47. Steen VD, Medsger TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000; 43: 2437-44.
48. Magnant J, de Monte M, Guilmot JL, Lasfargues G, Diot P, Asquier E et al. Relationship between occupational risk factors and severity markers of systemic sclerosis. J Rheumatol. 2005; 32: 1713-8.
49. Leroy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988; 15: 202-5.
50. Diot E, Boissinnot E, Asquier E, Guilmot JL, Lemarié E, Valat C et al. Relationship between abnormalities on high resolution CT and pulmonary function in systemic sclerosis. Chest. 1998; 114: 1623-9.
51. Leask A, Holmes A, Black CM, Abraham DJ. Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J Biol Chem. 2003.278; 13008-15.